Brief: Ryvu Therapeutics Says Total Non-Cash Expense From Incentive Programme Will Amount To PLN 51-62 Mln Spread Over 2021-2024
May 13 (Reuters) - Ryvu Therapeutics SA RVU.WA :
* TOTAL NON-CASH EXPENSE FROM INCENTIVE PROGRAMME WILL
AMOUNT TO
PLN 51-62 MILLION SPREAD OVER 2021-2024
* COST OF PROGRAM WILL BE INCLUDED IN COMPANY'S QUARTERLY
FINANCIAL STATEMENTS
Source text for Eikon: ID:nEM2nQbjba
Further company coverage: RVU.WA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Ryvu Therapeutics SA
See all newsBrief: Ryvu Therapeutics Signs Grant Agreement For Panacea-Novo Project With The National Center For Research And Development
Brief: Ryvu Therapeutics Q2 Net Loss 13.1 Million Zlotys
Brief: Ryvu Therapeutics "Dualis" Project Recommended For 22.2 Mln Zloty Subsidy
Brief: Ryvu Therapeutics Launches Early Clinical Development Services Business For Biotech And Pharma In Europe
Brief: Ryvu Therapeutics Says Panacea-Novo Project Recommended For Funding Of 106.7 Mln Zlotys